Researcher Spotlight: Andrew Jallouk, MD, PhD Vanderbilt University Medical Center Errol M. Cook Memorial Scholar Chimeric antigen receptor (CAR) T-cell therapy represents a highly effective treatment option for many types of lymphoma. Currently available CAR T-cell therapies are engineered on…
Researcher Spotlight: Alexander Boardman, MD Memorial Sloan Kettering Dobosh Family Scholar Treatment of lymphoma has been revolutionized by the emergence of CD19-directed chimeric antigen receptor (CAR) T-cell therapies, but many patients still relapse after treatment. Dr. Boardman’s LRF research seeks…
Researcher Spotlight: Ajilan Al Zaki, MD, PhD MD Anderson Cancer Center Chimeric antigen receptor (CAR) T-cell therapies represent a meaningful treatment option for lymphoma, but many patients who receive these therapies will experience side effects caused by inflammation. In some…
Researcher Spotlight: Alexandre Vinaud Hirayama, MD Fred Hutchinson Cancer Research Center Chimeric antigen receptor (CAR) T cell therapy is a typeof immunotherapy that genetically modifies a patient’simmune cells to recognize and kill tumor cells. “CAR T cell therapy has shown…
Researcher Spotlight: Marco Ruella, MD Perelman School of Medicine, University of Pennsylvania Chimeric antigen receptor (CAR) T cell therapy has been very successful in certain cancers, such as B-cell leukemia and lymphoma. However, the needle has not moved for most…
Researcher Spotlight: Natalie Grover, MD The University of North Carolina at Chapel Hill Although a majority of patients with Hodgkin lymphoma (HL) are cured with first-line therapy; about 15 percent of those patients experience primary refractory disease or relapse after…
Researcher Spotlight: Yong Gu Lee, PhD The Trustees of the University of Pennsylvania Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) and is the most common hematologic malignancy in the US. The prognosis…
Researcher Spotlight: Raghuveer Ranganathan, MD University of North Carolina, Chapel Hill Though CAR T-cell therapy has been successful for many patients with Non-Hodgkin lymphomas, the nature of the two versions currently approved by the FDA can have some severe side…
Researcher Spotlight: Irene Scarfo, PhD Massachussetts General Hospital The majority of chimeric antigen receptor (CAR) T-cell therapies currently being tested in lymphoma, including both therapies that have received U.S. Food and Drug Administration (FDA) approval, target CD19 antigen, and rely…